Endocrinologia Clínica (Lúcio Vilar) - 6 Edição_Parte231

Prévia do material em texto

35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009; 12:256-60.
Kaltsas GA, Nomikos P, Kontogeorgos G et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin
Endocrinol Metab. 2005; 90:3089-99.
Chatzellis E, Alexandraki KI, Androulakis II et al. Aggressive pituitary tumors. Neuroendocrinology. 2015; 101:87-104.
Alimohamadi M, Ownagh V, Mahouzi L et al. The impact of immunohistochemical markers of Ki-67 and p53 on the long-
term outcome of growth hormone-secreting pituitary adenomas: a cohort study. Asian J Neurosurg. 2014; 9:130-6.
Ruebel KH, Leontovich AA, Jin L et al. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by
high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocr J. 2006;
29:435-44.
Wierinckx A, Auger C, Devauchelle P et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of
prolactin pituitary tumors. Endocr Relat Cancer. 2007; 14:887-900.
Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol. 2012; 49:R69-78.
Kawashima ST, Usui T, Sano T et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing’s disease. Clin
Endocrinol (Oxf). 2009; 70:656-7.
Tfelt-Hansen J, Kunparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis.
Clin Med Res. 2006; 4:130-7.
Xiao JQ, Liu XH, Hou B et al. Correlations of pituitary tumor transforming gene expression with human pituitary
adenomas: a meta-analysis. PLoS One. 2014; 9:e90396.
Li Y, Zhou LP, Ma P et al. Relationship of PTTG expression with tumor invasiveness and microvessel density of pituitary
adenomas: a meta-analysis. Genet Test Mol Biomarkers. 2014; 18:279-85.
Filippella M, Galland F, Kujas M et al. Pituitary tumour transforming gene (PTTG) expression correlates with the
proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin
Endocrinol (Oxf). 2006; 65:536-43.
Delgrange E, Trouillas J, Maiter D et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation
marker study. J Clin Endocrinol Metab. 1997; 82:2102-7.
Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 1969; 16:185-217.
Chiloiro S, Doglietto F, Trapasso B et al. Typical and atypical pituitary adenomas: a single-center analysis of outcome and
prognosis. Neuroendocrinology. 2015; 101:143-50.
Rotondo F, Cusimano M, Scheithauer BW et al. Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
Hormones (Athens). 2012; 11:94-100.
Heaney A. Management of aggressive pituitary adenomas and pituitary carcinomas. J Neuro-oncol. 2014; 117:459-68.
Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol.
2014; 170:R213-27.
Zornitzki T, Knobler H, Nass D et al. Increased MIB-1/Ki-67 labeling index as a predictor of an aggressive course in a case
of prolactinoma. Horm Res. 2004; 61:111-6.
Molitch ME. Management of medically refractory prolactinoma. J Neuro-oncol. 2014; 117:421-8.
Mercado M, Espinosa E, Ramírez C. Current status and future directions of the pharmacological therapy of acromegaly.
Minerva Endocrinol. 2015 Oct 20. [Epub ahead of print.]
Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G et al. Octreotide LAR treatment of acromegaly in “real life”: long-
term outcome at a tertiary care center. Pituitary. 2015; 18:290-6.
 Ramos-Leví AM, Bernabeu I, Álvarez-Escolá C et al. Long-term treatment with pegvisomant for acromegaly: a 10-year
experience. Clin Endocrinol (Oxf). 2015. [Epub ahead of print.]
Hofland LJ, van der Hoek J, Feelders R et al. The multiligand somatostatina analogue SOM230 inhibits ACTH secretion by
cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005; 152:645-54.
Cuevas-Ramos D, Fleseriu M. Treatment of Cushing’s disease: a mechanistic update. J Endocrinol. 2014; 223:R19-39.
Simeoli C, Auriemma RS, Tortora F et al. The treatment with pasireotide in Cushing’s disease: effects of long-term
treatment on tumor mass in the experience of a single center. Endocrine. 2015; 50:725-40.
Vilar L, Naves LA, Machado MC et al. Medical combination therapies in Cushing’s disease. Pituitary. 2015; 18:253-62.
Hart MG, Garside R, Rogers G et al. Temozolomide for high grade glioma. Cochrane Database Syst Rev.
2013;4:CD007415.
Pietrantonio F, Perrone F, De Braud F et al. Activity of temozolomide in patients with advanced chemorefractory colorectal
cancer and MGMT promoter methylation. Ann Oncol. 2014;25:404-8.
Quirt I, Verma S, Petrella T et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist.
2007;12:1114-23.
	Endocrinologia Clínica (Lúcio Vilar) - 6ª Edição